INCYTE Corporation (INCY)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
CEO:
Hervé Hoppenot
Employees:
700
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE 19803
3024986700

Incyte Corp. is a biopharmaceutical company, which focuses on the discovery, development, development, formulation, manufacturing and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. Its product, Jakafi, a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers. The companywas founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Data derived from most recent annual or quarterly report
Market Cap 16.573 Billion Shares Outstanding221.325 Million Avg 30-day Volume 1.4 Million
P/E Ratio17.1838 Dividend Yield0.0 EPS
Price to Revenue5.4584 Debt to Equity0.0098 EBITDA654.268 Million
Price to Book Value4.3237 Operating Margin19.6157 Enterprise Value13.766 Billion
Current Ratio3.651 EPS Growth4.14 Quick Ratio3.47
1 Yr BETA 0.5422 52-week High/Low 88.26 / 61.91 Profit Margin31.7648
Operating Cash Flow Growth701.5201 Altman Z-Score9.7412 Free Cash Flow to Firm -199.2 Million
Earnings Report2022-08-02
View SEC Filings from INCY instead.

View recent insider trading info

Funds Holding INCY (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding INCY BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

44 Thousand total shares from 4 transactions

Exercise Derivative Conversion (M)

41.9 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

PASQUALE MARIA E EVP & GENERAL COUNSEL

  • Officer
53,058 2022-04-09 7

FLANNELLY BARRY P EVP & GENERAL MANAGER US

  • Officer
65,163 2022-04-08 5

BAKER BROS. ADVISORS LP

667, L.P.

BAKER JULIAN

BAKER BROS. ADVISORS (GP) LLC

BAKER BROTHERS LIFE SCIENCES LP

BAKER FELIX

  • Director
  • 10% Owner
36,675,682 2022-03-31 9

HARRIGAN EDMUND

  • Director
5,572 2022-03-31 4

DIXON WENDY L

  • Director
17,768 2022-03-31 6

FOUSE JACQUALYN A

  • Director
8,511 2022-03-31 5

CLANCY PAUL J

  • Director
8,290 2022-03-31 5

TRAY THOMAS PRINCIPAL ACCOUNTING OFFICER

  • Officer
15,918 2022-03-11 1

STAMOULIS CHRISTIANA EVP & CHIEF FINANCIAL OFFICER

  • Officer
56,285 2022-02-11 5

DICKINSON JONATHAN ELLIOTT EVP, GENERAL MANAGER, EUROPE

  • Officer
30,214 2022-01-31 5

MORRISSEY MICHAEL JAMES EVP, HEAD OF TECH. OPERATIONS

  • Officer
55,610 2022-01-24 4

SWAIN PAULA J EVP, HUMAN RESOURCES

  • Officer
15,054 2022-01-19 6

HOPPENOT HERVE CHAIRMAN / CEO

  • Officer
  • Director
  • PRESIDENT
84,852 2022-01-19 3

TROWER PAUL PRINCIPAL ACCOUNTING OFFICER

  • Officer
3,250 2022-01-19 3

IYENGAR VIJAY K EVP GPS, BD, & LICENSING

  • Officer
15,054 2022-01-19 5

STEIN STEVEN H EVP & CHIEF MEDICAL OFFICER

  • Officer
15,054 2022-01-19 5

DHANAK DASHYANT EVP & CHIEF SCIENTIFIC OFFICER

  • Officer
15,054 2022-01-19 11

BRAWLEY OTIS W

  • Director
0 2021-09-27 2

WENQING YAO EVP, HEAD OF DISCOVERY CHEM

  • Officer
212,609 2021-07-02 2

BIENAIME JEAN JACQUES

  • Director
18,854 2021-05-26 1

HIGH KATHERINE A

  • Director
11,354 2021-05-26 1

FRIEDMAN PAUL A

  • Director
271,813 2020-05-26 0

BROOKE PAUL A

  • Director
261,911 2020-03-31 0

BAKER BROS. ADVISORS LP

14159, L.P.

667, L.P.

BAKER BROS. ADVISORS (GP) LLC

BAKER BROTHERS LIFE SCIENCES LP

BAKER FELIX

BAKER JULIAN

  • Director
  • 10% Owner
32,431,899 2019-06-06 9

GRYSKA DAVID W EXECUTIVE VICE PRESIDENT, CFO

  • Officer
10,235 2018-07-16 0

HUBER REID M EVP, CHIEF SCIENTIFIC OFFICER

  • Officer
34,571 2018-07-16 0

SIEGEL ERIC H. EVP, GENERAL COUNSEL

  • Officer
21,053 2017-09-13 0

LEVY RICHARD S EVP, CHIEF DRUG DEV OFFICER

  • Officer
16,926 2016-01-06 0

DALY JAMES M EVP, CHIEF COMMERCIAL OFFICER

  • Officer
3,521 2015-06-23 0

CHARDONNET LAURENT

  • VICE PRESIDENT AND TREASURER
2,905 2015-03-30 0

ARIKO BARRY A

  • Director
45,834 2015-03-12 0

DE SCHUTTER RICHARD U

  • Director
  • CHAIRMAN
92,290 2015-03-05 0

HASTINGS DAVID C CHIEF FINANCIAL OFFICER

  • Officer
8,500 2014-06-04 0

WHITFIELD ROY A

  • Director
666,082 2013-12-17 0

BAKER BROS. ADVISORS (GP) LLC

  • Director
  • 10% Owner
0 2013-07-01 0

BAKER JULIAN

BAKER FELIX

BAKER BROS ADVISORS LLC

667, L.P.

BAKER BROTHERS LIFE SCIENCES LP

14159, L.P.

  • Director
  • 10% Owner
15,023,952 2013-06-11 0

BAKER BROTHERS LIFE SCIENCES LP

  • Director
12,445,783 2013-06-11 0

14159, L.P.

  • Director
370,839 2013-06-11 0

667, L.P.

  • Director
2,038,937 2013-06-11 0

BAKER JULIAN

  • Director
  • 10% Owner
0 2013-05-30 0

FBB ASSOCIATES

  • Director
  • 10% Owner
33,410 2012-06-15 0

FBB2 LLC

  • Director
  • 10% Owner
15,110 2012-06-15 0

BAKER BROS ADVISORS LLC

  • Director
  • 10% Owner
0 2012-04-12 0

ANDREWS PATRICIA S CHIEF COMMERCIAL OFFICER

  • Officer
0 2012-01-19 0

BAKER BROTHERS LIFE SCIENCES CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • Director
  • 10% Owner
12,430,783 2012-01-12 0

14159 CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • Director
  • 10% Owner
355,839 2012-01-12 0

BAKER BROS. CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • Director
  • 10% Owner
227,594 2011-06-30 0

NIBLACK JOHN F

  • Director
0 2011-05-20 0

SCHRECK PATRICIA A EVP, GENERAL COUNSEL

  • Officer
4,500 2011-05-09 0

METCALF BRIAN W CHIEF DRUG DISCOVERY SCIENTIST

  • Officer
66,504 2011-04-11 0

BAKER BIOTECH CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • Director
  • 10% Owner
2,933,021 2010-09-21 0

BAKER / TISCH CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • Director
  • 10% Owner
159,739 2010-09-21 0

FRIEDMAN STEVEN M. EVP, BIOLOGY & PRECLINICAL DEV

  • Officer
0 2010-05-18 0

EMMENS MATTHEW

  • Director
0 2008-05-22 0

KELLER JOHN A CHIEF BUSINESS OFFICER

  • Officer
0 2008-02-08 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

PASQUALE MARIA E - Officer EVP & GENERAL COUNSEL

2022-04-12 16:12:45 -0400 2022-04-09 F 517 $80.95 d 53,058 direct -0.3049 -6.2569 0.0 1 -6.2569 6

FLANNELLY BARRY P - Officer EVP & GENERAL MANAGER US

2022-04-12 16:10:17 -0400 2022-04-08 M 20,516 d 0 direct

FLANNELLY BARRY P - Officer EVP & GENERAL MANAGER US

2022-04-12 16:10:17 -0400 2022-04-08 M 21,348 d 0 direct

FLANNELLY BARRY P - Officer EVP & GENERAL MANAGER US

2022-04-12 16:10:17 -0400 2022-04-08 S 881 $82.96 d 66,411 direct yes -0.3049 -6.2569 0.0 1 -6.2569 6

FLANNELLY BARRY P - Officer EVP & GENERAL MANAGER US

2022-04-12 16:10:17 -0400 2022-04-08 S 20,516 $83.01 d 67,292 direct yes -0.3049 -6.2569 0.0 1 -6.2569 6

FLANNELLY BARRY P - Officer EVP & GENERAL MANAGER US

2022-04-12 16:10:17 -0400 2022-04-08 S 21,348 $84.00 d 67,292 direct yes -0.3049 -6.2569 0.0 1 -6.2569 6

FLANNELLY BARRY P - Officer EVP & GENERAL MANAGER US

2022-04-12 16:10:17 -0400 2022-04-08 M 20,516 $68.62 a 87,808 direct -0.3049 -6.2569 0.0 1 -6.2569 6

FLANNELLY BARRY P - Officer EVP & GENERAL MANAGER US

2022-04-12 16:10:17 -0400 2022-04-08 M 21,348 $72.27 a 88,640 direct -0.3049 -6.2569 0.0 1 -6.2569 6

FLANNELLY BARRY P - Officer EVP & GENERAL MANAGER US

2022-04-12 16:10:17 -0400 2022-04-08 S 1,248 $82.96 d 65,163 direct yes -0.3049 -6.2569 0.0 1 -6.2569 6

DIXON WENDY L - Director

2022-04-04 16:00:32 -0400 2022-03-31 A 249 $79.42 a 17,768 direct 1.4498 -0.7807 -9.0582 3.0731 4 -9.9752 24

HARRIGAN EDMUND - Director

2022-04-04 16:00:49 -0400 2022-03-31 A 240 $79.42 a 5,572 direct 1.4498 -0.7807 -9.0582 3.0731 4 -9.9752 24

FOUSE JACQUALYN A - Director

2022-04-04 16:00:51 -0400 2022-03-31 A 280 $79.42 a 8,511 direct 1.4498 -0.7807 -9.0582 3.0731 4 -9.9752 24

BAKER BROS. ADVISORS LP - Director - > 10% Owner see footnotes

667, L.P. - Director - > 10% Owner see footnotes

BAKER JULIAN - Director - > 10% Owner see footnotes

BAKER BROS. ADVISORS (GP) LLC - Director - > 10% Owner see footnotes

BAKER BROTHERS LIFE SCIENCES LP - Director - > 10% Owner see footnotes

BAKER FELIX - Director - > 10% Owner see footnotes

2022-04-04 16:54:39 -0400 2022-03-31 A 440 a 33,419,495 indirect 1.4498 -0.7807 -9.0582 3.0731 4 -9.9752 24

CLANCY PAUL J - Director

2022-04-04 16:00:16 -0400 2022-03-31 A 326 $79.42 a 8,290 direct 1.4498 -0.7807 -9.0582 3.0731 4 -9.9752 24

BAKER BROS. ADVISORS LP - Director - > 10% Owner see footnotes

667, L.P. - Director - > 10% Owner see footnotes

BAKER JULIAN - Director - > 10% Owner see footnotes

BAKER BROS. ADVISORS (GP) LLC - Director - > 10% Owner see footnotes

BAKER BROTHERS LIFE SCIENCES LP - Director - > 10% Owner see footnotes

BAKER FELIX - Director - > 10% Owner see footnotes

2022-04-04 16:54:39 -0400 2022-03-31 A 440 a 2,941,587 indirect 1.4498 -0.7807 -9.0582 3.0731 4 -9.9752 24

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
INCYTE CORP INCY 2022-05-20 22:15:03 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 21:45:03 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 21:15:03 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 20:45:03 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 20:15:05 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 19:45:03 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 19:15:04 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 18:45:03 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 18:15:03 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 17:45:03 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 17:15:03 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 16:45:04 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 16:15:03 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 15:45:03 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 15:15:03 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 14:45:03 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 14:15:04 UTC 0.4119 0.4081 4200000
INCYTE CORP INCY 2022-05-20 13:45:03 UTC 0.4119 0.4081 4100000
INCYTE CORP INCY 2022-05-20 13:15:03 UTC 0.4119 0.4081 4100000
INCYTE CORP INCY 2022-05-20 12:45:03 UTC 0.4119 0.4081 3700000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
AGF Investments Trust- AGFIQ U.S. Market Neutral Momentum Fund INCY -292.0 shares, $-25398.16 2020-12-31 N-PORT
FundVantage Trust- Gotham Absolute 500 Core Fund INCY -59.0 shares, $-4320.57 2020-03-31 N-PORT
M3Sixty Funds Trust- AXS Market Neutral Fund INCY -1059.0 shares, $-92111.82 2020-12-31 N-PORT
Nuveen Investment Trust- Nuveen Equity Market Neutral Fund INCY -2100.0 shares, $-175938.0 2021-05-31 N-PORT
ADVISORS' INNER CIRCLE FUND II- Hancock Horizon Quantitative Long/Short Fund INCY -3670.0 shares, $-308757.1 2021-06-30 N-PORT
AQR Funds- AQR Alternative Risk Premia Fund INCY -177.0 shares, $-12991.8 2021-12-31 N-PORT
INVESTMENT MANAGERS SERIES TRUST II- AXS Market Neutral Fund INCY -885.0 shares, $-70286.7 2022-03-31 N-PORT

Elevate your investments